Application of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload
Launched by BEIJING ANZHEN HOSPITAL · Oct 27, 2024
Trial Information
Current as of September 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of Tricuspid valve insufficiency; must understand the purpose of the study and signed an informed consent form;
- Exclusion Criteria:
- • Combined coronary artery stenosis; Combined with aortic aneurysm related diseases; Patients with congenital heart disease;
About Beijing Anzhen Hospital
Beijing Anzhen Hospital is a leading medical institution in China, renowned for its expertise in cardiovascular diseases and comprehensive healthcare services. As a prominent clinical trial sponsor, the hospital is dedicated to advancing medical research and innovation, facilitating the development of new therapies and treatment protocols. With a focus on patient safety and ethical standards, Beijing Anzhen Hospital collaborates with various research entities to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing the understanding of cardiovascular health. Its commitment to excellence in clinical research is underscored by a multidisciplinary team of experienced healthcare professionals and a state-of-the-art facility equipped to support a wide range of clinical investigations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported